Reflux disease and Barrett's esophagus

Endoscopy

Volumn 32, Issue 2, 2000, Pages 101-107

  Koop, H ^a  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH FUNDOPLICATION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 0033973385     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-143     Document Type: Review

References (45)

1. Trudgill NJ, Kapur KC, Rilcy SA. Familial clustering of reflux symptoms. Am J Gastroenterol 1999; 94: 1172-1178
2. Contractor QQ, Akhtar SS, Contractor TQ. Endoscopie esophagitis and gastrocsophageal flap valve. J Clin Gastroenterol 1999; 28: 233-237
3. Lundell L, Dent J, Bennett JR, et al. Endoscopie assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-180
4. Stal P, Lindberg G, Ost A, et al. Gastroesophageal reflux in healthy subjects: significance of endoscopie Findings, histology, age and sex. Scand J Gastroenterol 1999; 34: 121-128
5. s Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled trial. Aliment Pharmacol Ther 1999; 13: 907-914
6. Blustein PK, Beck PL, Meddings JB, et al. The utility of endoscopy in the management of patients with gastrocsophageal reflux symptoms. Am J Gastroenterol 1998; 93: 25082512
7. Sonnenberg A, Delco F, El-Serag HB. Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis. Dig Dis Sei 1998; 43: 1001-1008
8. Wu JCY, Sung JJY, Ng EK.W, et al. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East. Am J Gastroenterol 1999; 94: 1790-1794
9. El-Serag HB, Sonnenberg A, Jamal MM, et al. Corpus gastritis is protective against reflux oesophagitis. Gut 1999; 45: 181185
10. Vicari JJ, Peek RM, Falk GV, et al. The seroprevalence of c7g/l-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-57
11. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton-pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-16
12. Schenk BE, Kuipcrs EJ, Klinkenberg-Knol EC, et al. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 884887
13. Lundcll L, Micttinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999; 117:319-326"
14. Peters JH, DeMcester TR, Crookes P, et al. The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication: prospective evaluation of 100 patients with "typical" symptoms. Ann Surg 1998; 228: 40-50
15. Van der Peet DL, Klinkenberg-Knol EC EC, Eijsbouts QA, et al. Laparoscopic Nissen fundoplication for the treatment of gastroesophageal reflux disease (GERD): surgery after extensive conservative treatment. Surg Endosc 1998; 12: 1159
16. Csendes A, Braghetto A, Burdiles P, et al. Long-term results of classic antireflux surgery in 152 patients with Barren's esophagus: clinical, radiologie, endoscopie, manometric, and acid reflux test analysis before and late after operation. Surgery 1998; 123: 645-657
17. El-Sarag HB, Sonnenberg A. Outcome of erosive reflux esophagitis after Nissen fundoplication. Am J Gastroenterol 1999; 94: 1771-1776
18. Murphy PP, Ballinger PJ, Massey BT, et al. Discrete ulcers in Barren's esophagus: relationship to acute gastrointestinal bleeding. Endoscopy 1998; 30: 367-370
19. Lagergren J, Bergstrm R, Lindgren A, Nyrn O. Symptomatic gastroesophageal reflux as a risk factor for esophageaiadehocarcinoma. N Engl J Med 1999; 340: 825-831
20. Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barren's esophagus: a population-based study. Am J Gastroenterol 1999; 94: 86-91
21. Eloubeidi MA, Provenzale D. Does this patient have Barren's esophagus? The utility of predicting Barren's esophagus at the index endoscopy. Am J Gastroenterol 1999; 94: 937-943
22. El-Serag HB, Sonnenberg A, Jamal MM, et al. Characteristics of intestinal metaplasia in the gastric cardia. Am J Gastroenterol 1999; 94: 622-627
23. Hirota VK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116: 277-285
24. Pcreira AD, Suspiro A, Chaves P, et al. Short segments of Barren's epithelium and intestinal metaplasia in normal appearing esophagogastric junctions: the same or two different entities? Gut 1998; 42: 659-662
25. Voutilainen M, Farkkila M, Juhola RI, et ai. Spezialized columnar epithelium of the esophagogastric junction: prevalence and associations (The Central Finland Endoscopy Study Group). Am J Gastroenterol 1999; 94: 913-918
26. Byrne JP, Bhatnagar S, Hamid B, et al. Comparative study of intestinal metaplasia and mucin staining at the cardia and esophagogastric junction in 225 symptomatic patients presenting for diagnostic open-access gastroscopy. Am J Gastroenterol 1999; 94: 98-103
27. Falk GW, Rice TW, Goldblum JR, Richter JE. Jumbo forceps protocol still misses unsuspected cancer in Barren's esophagus with high-grade dysplasia. Gastrointest Endosc 1999; 49: 170176
28. Morales TG, Bhattacharyya A, Camargo E, et al. Mthylne blue staining for intestinal metaplasia of the gastric cardia with follow-up dysplasia. Gastrointest Endosc 1998; 48: 26-31
29. Gueltrud M, Herrera I. Acetic acid improves identification of remnant islands of Barrett's epithelium after endoscopie therapy. Gastrointest Endosc 1998; 47: 512-515
30. Smith AM, Maxwell-Armstrong CA, Welch NT, Schoiefield JH. Surveillance for Barrett's oesophagus in the UK. Br J Surg 1999; 86: 276-280
31. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus. Am J Gastroenterol 1999; 94: 2037-2042
32. Gulizia JM, Wang H, Antonioli D, et al. Proliferative characteristics of intestinal mucosa in the distal esophagus and gastroesophageal junction (short-segment esophagus): a case-control study. Hum Pathol 1999; 30: 412-418
33. Ouatu-Lescar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-335
34. Ouatu-Lescar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93: 711-716
35. Cooper BT, Neumann CS, Cox NA, Iqbal TH. Continuous treatment with omeprazole 20 mg for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12: 893-897
36. Low DE, Levine DS, Dail DH, Kozarek RA. Histological and anatomic changes in Barrett's esophagus after antireflux surgery. Am J Gastroenterol 1999; 94: 80-85
37. Peters FTM, Ganesh S, Kuipers EJ, et al. Endoscopie regression of Barrett's oesophagus during omeprazole treatment: a randomised double-blind study. Gut 1999; 45: 489-494
38. Kovacs BJ, Chen YK, Lewis TD, et al. Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression. Gastrointest Endosc 1999; 49: 547-553
39. Byrne JP, Armstrong GR, Attwood SEA. Restoration of normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998; 93: 1810-1815
40. Mork H, Barth T, Kreipe HH, et al. Reconstitution of squamous epithelium in Barrett's oesophagus with endoscopie argon plasma coagulation: a prospective study. Scand J Gastroenterol 1998; 33: 1130-1134
41. Grade AJ, Shah IA, Medlin SM, Ramirez FC. The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus. Gastrointest Endosc 1999; 50: 18-22
42. Van Laethem JL, Cremer M, Peny MO, et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid-term results. Gut 1998; 43: 747751
43. Gossner L, May A, Stolte M, et al. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest Endosc 1999; 49: 8-12
44. Sharma P, Jaffe PE, Bhattacharyya A, Sampliner RE. Laser and multipolar electrocoagulation ablation in early Barrett's adenocarcinoma: long-term follow-up. Gastrointest Endosc 1999; 49: 442-446
45. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49: 1-7